SCM
ELVN icon

Soleus Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Soleus Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.05M Sell
230,869
-794,131
-77% -$22M 0.37% 55
2025
Q4 		$15.8M Buy
+1,025,000
New +$20.4M 0.58% 44
2025
Q1 		– Sell
-75,405
Closed -$1.7M – 82
2024
Q4 		$1.7M Sell
75,405
-164,300
-69% -$4.26M 0.11% 69
2024
Q3 		$6.12M Sell
239,705
-529,558
-69% -$12.3M 0.47% 51
2024
Q2 		$18M Buy
+769,263
New +$16.2M 1.59% 24

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Soleus Capital Management's ELVN Position: Q1 2026 in Review

Soleus Capital Management reduced its Enliven Therapeutics (ELVN) stake by 77% in Q1 2026, selling an estimated $22M and leaving 230,869 shares worth $9.05M. The position accounts for 0.37% of the portfolio, ranked #55.

Soleus Capital Management first reported a position in ELVN in Q2 2024 and has held it in 5 quarters since. The position peaked at $18M in Q2 2024. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Soleus Capital Management held 230,869 shares of Enliven Therapeutics worth $9.05M as of Q1 2026.
  • Soleus Capital Management sold 794,131 Enliven Therapeutics shares in Q1 2026, an estimated $22M.
  • Enliven Therapeutics made up 0.37% of Soleus Capital Management's portfolio in Q1 2026, its #55 holding.
  • Soleus Capital Management first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Soleus Capital Management's Enliven Therapeutics position peaked at $18M in Q2 2024.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.